AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Liver TransplantationTransplantation, AutologousTransplantation, HomologousKidney TransplantationBone Marrow TransplantationHematopoietic Stem Cell TransplantationHeart TransplantationLung TransplantationStem Cell TransplantationTransplantation ConditioningGraft SurvivalOrgan TransplantationGraft RejectionPancreas TransplantationIslets of Langerhans TransplantationTissue DonorsCell TransplantationTransplantationTransplantation ImmunologyTransplantation ChimeraTreatment OutcomeImmunosuppressive AgentsGraft vs Host DiseaseTransplantation, IsogeneicLiving DonorsTransplantation, HeterotopicCord Blood Stem Cell TransplantationPeripheral Blood Stem Cell TransplantationHeart-Lung TransplantationRetrospective StudiesTime FactorsTissue and Organ ProcurementTransplantation ToleranceBlood Transfusion, AutologousImmunosuppressionHistocompatibility TestingLiver FailureFetal Tissue TransplantationRecurrenceSkin TransplantationPostoperative ComplicationsMesenchymal Stem Cell TransplantationWhole-Body IrradiationTransplantation, HeterologousHematologic NeoplasmsWaiting ListsTissue TransplantationFollow-Up StudiesHistocompatibilityCombined Modality TherapySurvival AnalysisCorneal TransplantationSurvival RateTacrolimusCyclosporineCadaverBusulfanRemission InductionMelphalanBrain Tissue TransplantationCyclophosphamideLiver DiseasesFacial TransplantationHLA AntigensDonor SelectionMultiple MyelomaOrgan PreservationLeukemiaTransplantsT-LymphocytesHematopoietic Stem CellsMyeloablative AgonistsLymphoma, Non-HodgkinDisease-Free SurvivalKidney Failure, ChronicAntineoplastic Combined Chemotherapy ProtocolsRisk FactorsAntilymphocyte SerumAcute DiseasePrognosisHematopoietic Stem Cell MobilizationBronchiolitis ObliteransTissue and Organ HarvestingAnemia, AplasticCytomegalovirus InfectionsBone Marrow PurgingAntigens, CD34Prospective StudiesMice, Inbred C57BLPostoperative PeriodRats, Inbred LewSalvage TherapyHand TransplantationBlood Group IncompatibilityBone Marrow CellsMycophenolic AcidCarmustineLeukemia, Myeloid, AcuteCell DifferentiationCells, Cultured
ASCTBonePatient'sDescribing an autologous stemHaematopoietic stemRemissionSurvivalCell TransplantationProgenitor cellsHeart transplantationPatients2022ImmunologyRefractoryTransplantStem cell transplantsKidney transplantationTransplantsLymphoproliferative disordersProcedureMSCsHematopoietic progenitorsRecipientsTherapyAcuteMyocardial infarctionTreatmentSignificantlyUndergoneClinicalAutogenousAHSCTPatientDoseImmunosuppressionPostoperativeOutcomesImmuneDonorRegimen
ASCT8
  • High-dose melphalan and autologous stem cell transplantation (HDM/ASCT) is widely used in immunoglobulin light chain (AL) amyloidosis, but the benefit is debated mainly because of the high treatment-related mortality (24% in a randomised study comparing HDM/ASCT with oral melphalan/dexamethasone). (lu.se)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • High-dose chemotherapy with autologous stem-cell rescue (HDC/ASCT) is the best salvage therapy for patients with aggressive B-cell lymphomas. (cun.es)
  • In this ongoing Phase II multicenter study, 55 heavily pretreated patients with relapsed/refractory DLBCL, including almost 50% without a response to autologous stem cell transplantation (ASCT), were treated with fludarabine/cyclophosphamide lymphodepletion, followed by a dose of JCAR17. (medpagetoday.com)
  • The aim of this study is to evaluate the prognostic impact of myeloid-derived suppressor cells (MDSCs) in multiple myeloma (MM) in the context of autologous stem cell transplantation (ASCT). (biomedcentral.com)
  • Both MDSC phenotypes pre-ASCT but not post-ASCT similarly suppressed in vitro autologous T and natural killer T cell proliferation. (biomedcentral.com)
  • High-dose chemotherapy and autologous stem cell transplantation (HCT-ASCT) after high-dose methotrexate (MTX)-based immuno-chemotherapy has become an increasingly used treatment approach in eligible elderly PCNSL patients with promising feasibility and efficacy, but has not been compared with conventional chemotherapy approaches. (biomedcentral.com)
  • We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients. (e-crt.org)
Bone23
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
  • The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
  • Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
  • The present report describes an incomplete atypical femoral fracture (AFF) patient who underwent simultaneous autogenous bone transplantation to the resected fracture region during intramedullary nail fixation. (hindawi.com)
  • At 7 months after surgery, radiographs demonstrated complete bone repair, and no clinical problems were observed two years postoperatively. (hindawi.com)
  • To the best of our knowledge, this is the first report in which autogenous bone marrow transplantation, noninvasive to the iliac crest, was performed in an incomplete AFF patient. (hindawi.com)
  • Anteroposterior radiographs showing fracture region just after surgery (c) and complete bone repair at 7 months after surgery (d). (hindawi.com)
  • Autologous transplantation is feasible when the patient's bone marrow is normal and there are no relevant genetic conditions. (medscape.com)
  • At 1 and 6 months after completion of chemotherapy, she presented with anasarca and was diagnosed with relapse exclusively in the bone marrow twice. (karger.com)
  • Diffuse alveolar hemorrhage (DAH) is a non-infectious pulmonary complication of bone marrow transplantation (BMT) with resultant high mortality. (nih.gov)
  • In experimental and clinical studies unselected mononuclear bone marrow cells as well as specific subpopulations have been used for transplantation. (escardio.org)
  • Primary end points were reduction in insulin requirement by ≥50% and improvement in glucagon-stimulated C-peptide levels at the end of 6 months of autologous bone marrow-derived stem cell transplantation (SCT), while secondary end points were a change in weight and HbA1c and lipid levels as compared to baseline. (drcalapai.com)
  • Treatment may include surgery, chemotherapy, radiotherapy and/or bone marrow transplantation. (khcc.jo)
  • Advanced stages of neuroblastoma are treated with intensive chemotherapy in combination with an autologous bone marrow transplant, which is usually followed by a vitamin A derivative administered orally for 6 months. (khcc.jo)
  • The clinical trial for 'Autologous Bone Marrow Progenitor Cell Treatment for Heart Failure,' at the University of Pittsburgh Medical Center is lead by Dr. Amit. (cellmedicine.com)
  • In the coming time, the hospital will continue to carry out autologous stem cell transplantation for pediatric patients with solid tumors and to implement allogeneic stem cell transplantation in the treatment of bone marrow failure, blood cancer or Thalassemia. (baothuathienhue.vn)
  • Patients who undergo bone marrow transplantation are generally immunosuppressed with a dose of cyclophosphamide which is usually calculated based on the patient's weight. (slideshare.net)
  • Peripheral blood has largely replaced bone marrow as a source of stem cells, especially in autologous hematopoietic stem cell transplantation, because stem cell harvest is easier and neutrophil and platelet counts recover faster. (msdmanuals.com)
  • Saja received her initial chemotherapy in Rabat, before returning home to Gaza in February 2020 to continue her treatment and undergo bone marrow transplantation in the occupied Palestinian territory. (who.int)
  • An initial appointment was scheduled for 22 March 2020 at An-Najah Hospital in Nablus, in the West Bank, but the hospital only offers autologous transplantation (using the patient's own bone marrow), while Saja needed an allogeneic transplant (with bone marrow from a donor). (who.int)
  • MM is considered relative paucity of CNS invasion by MM an incurable disease despite various meth- in comparison with other tumours, whether ods of treatment, including autologous bone solid or haematological, remain unknown, marrow transplantation [ 3 ]. (who.int)
Patient's3
  • Autologous limbal stem cell transplantation from the patient's other eye and another AMT were performed, resulting in stable corneal surface 2 months later ( Technical Appendix Figure, panel G). Neovascularization regressed, the cornea cleared, and vision improved ( Technical Appendix Figure, panels H, I). (cdc.gov)
  • After the transplantation, the patient's new lymphocytes or immune cells are self-tolerant and do not attack the immune system. (scienceblog.com)
  • Hematopoietic stem cell transplantation may be autologous (using the patient's own cells) or allogeneic (using cells from a donor). (msdmanuals.com)
Describing an autologous stem1
  • According to the authors, despite landmark studies describing an autologous stem cell approach over the past 25 years and similar methods being utilized in Europe, no U.S. research team had successfully developed a manufacturing process and quality control tests that met U.S. Food and Drug Administration (FDA) requirements or showed any clinical benefit. (worldhealth.net)
Haematopoietic stem2
  • Background: Effectiveness of autologous haematopoietic stem-cell transplantation (AHSCT) in relapsing-remitting multiple sclerosis (MS) is well known, but in secondary-progressive (SP-) MS it is still controversial. (unifi.it)
  • The procedure is called autologous non-myeloablative haematopoietic stem-cell transplantion. (scienceblog.com)
Remission4
  • Multivariable analysis revealed that creatinine ≥2 mg/dl, extramedullary disease, ≤very good partial remission and non-autologous hematopoietic stem cell transplantation are independent risk factors for shorter survival. (scielo.br)
  • PURPOSE: Salvage autologous stem-cell transplantation (sASCT) in patients with multiple myeloma (MM) relapsing after a prior autologous stem-cell transplantation leads to increased remission duration and overall survival. (ucl.ac.uk)
  • Interestingly, in one patient who relapsed after obtaining a CR following JCAR17 infusion, administration of a PD-1 inhibitor resulted in remission within 3 months, suggesting a potential resistance mechanism of immune escape which can be abrogated by PD-1 blockade. (medpagetoday.com)
  • Allogeneic transplantation was performed in five patients, two of whom achieved complete remission despite residual or refractory disease. (oncotarget.com)
Survival13
  • In patients with cardiac involvement or multiple organ involvement, survival was significantly shorter, median overall survival 49 and 56 months, respectively. (lu.se)
  • Although multiple myeloma patients younger than 66 years of age have an aggressive presentation, this did not translate into an inferior overall survival, particularly in those undergoing autologous hematopoietic stem cell transplantation. (scielo.br)
  • Survival is variable, depending on the different prognostic factors, ranging from months to more than 10 years. (scielo.br)
  • Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (smw.ch)
  • Median survival is about nine months. (wikipedia.org)
  • 70%) and poor long-term outcome with an overall survival of only 6 months ( 3 ). (frontiersin.org)
  • Autologous transplantation conferred relapse-free and overall survival benefit over chemotherapy consolidation alone, the current standard in the United States, and it might constitute a valuable option for ethnic/racial minorities. (elsevierpure.com)
  • Data obtained from the allogeneic and autologous transplantation models helped us identify a suitable immunosuppression regimen that allows cell survival and engraftment for up to the total duration of the studies (6 months). (ca.gov)
  • In addition, average progression-free survival was 2.6 months longer among Pixuvri-treated patients, at 10.2 months. (genengnews.com)
  • The overall response rate to first-line therapies with anthracycline-based regimens was poor (32%), with a median survival of only 6.9 months. (oncotarget.com)
  • Recipients of allogeneic transplantation had significantly improved overall survival compared to non-transplanted patients. (oncotarget.com)
  • Median progression-free survival among all 33 patients was 11.8 months (95% CI, 6.2-17.8). (eurekalert.org)
  • The confirmed relapse-free survival rate was 62.9% and progression-free survival rate was 83.3% after 91Â months according to Kaplan and Meier survival curves. (cellsurgicalnetwork.com)
Cell Transplantation35
Progenitor cells1
  • T-cell and B-cell reconstitution was studied in nine patients who received fluorescence activated cell sorter (FACS)-sorted autologous CD34 + hematopoietic progenitor cells (HPC). (elsevierpure.com)
Heart transplantation1
Patients37
  • Patients who undergo HSCT experience a sequential suppression of host defenses, resulting in varying infectious risk at different phases of the transplantation process. (medscape.com)
  • Dermabrasion versus microneedling in transplantation of autologous noncultured melanocyte-keratinocyte cell suspension in patients with vitiligo. (medscape.com)
  • This randomized comparative study aimed to assess the efficacy of transplanting autologous melanocyte-keratinocyte suspension in patients with stable vitiligo and to compare site preparation using dermabrasion vs microneedling. (medscape.com)
  • Twenty-six patients were infused with CART cells (median 81 days after leukapheresis) and were analyzed for the overall response (OR) 3 months later. (frontiersin.org)
  • Pain interference was higher (worse) in the sASCT group than in the NTC group at 6 months after random assignment (P = .0267), with patients with sASCT reporting higher scores for Pain interference with daily living for up to 2 years after random assignment. (ucl.ac.uk)
  • CONCLUSION: Patients with sASCT with relapsed MM demonstrated a comparative reduction in QoL and greater impact of treatment adverse effects lasting for 6 months and up to 2 years for pain, after which patients who had received sASCT reported better outcomes. (ucl.ac.uk)
  • As stated by the investigators, "To our knowledge, this is the first clinical trial designed to investigate concurrent treatment with a checkpoint inhibitor and conventional chemotherapy in relapsed or refractory classic[al] Hodgkin lymphoma in patients destined for an autologous SCT. (ascopost.com)
  • Patients with complete response proceeded to autologous SCT. (ascopost.com)
  • A total of 35 patients proceeded to autologous SCT. (ascopost.com)
  • The investigators concluded, "Results suggest that the addition of pembrolizumab to ICE chemotherapy was well tolerated and highly effective in comparison with prior reports of chemotherapy-only regimens, supporting further investigation in patients with relapsed or refractory classic[al] Hodgkin lymphoma eligible for an autologous SCT. (ascopost.com)
  • Six patients are alive with a median follow-up of 18 months (range 12-60). (nih.gov)
  • Remarkably, this high degree of response was preserved in high-risk patients, including those who were refractory to chemotherapy after transplantation, or had double/triple hit lymphomas. (medpagetoday.com)
  • Among 30 patients and 6 months after treatment, an average HbA1c level of 6.8% was achieved, and 71% of patients had levels that were at target, reported Sushela Chaidarun, MD, PhD , of Dartmouth-Hitchcock Medical Center in Lebanon, N.H., and colleagues. (medpagetoday.com)
  • The authors also reported at the Endocrine Society annual meeting that patients improved their diabetes-related outcomes after initially undergoing off-site islet isolation, during which the pancreas is taken out of the body (procedure done at Massachusetts General Hospital in Boston) before transitioning to on-site autologous islet transplantation. (medpagetoday.com)
  • After 12 months, the average HbA1c levels had risen to 7.5% with 62% of patients on target and 52% of patients requiring no insulin at all, they said. (medpagetoday.com)
  • Islet auto-transplantation either on-site or off-site islet isolation can be used to avert the burden of complicated and costly diabetic care for carefully selected patients requiring total or sub-total pancreatectomy," they wrote. (medpagetoday.com)
  • Cultivated autologous limbal epithelial cells (CALEC) procedure shown to be safe and feasible with early positive results of restored cornea surfaces or vision gains in four patients with severe chemical burns. (worldhealth.net)
  • According to the study published August 18 in Science Advances, the patients who were followed for 12 months experienced restored cornea surfaces -- two were able to undergo a corneal transplant and two reported significant improvements in vision without additional treatment. (worldhealth.net)
  • Patients on stable doses of medications for past 3 months were recruited. (drcalapai.com)
  • This experience supports the feasibility of sequential living donor KTx and autologous SCT for carefully selected patients with ESRD due to AL. (elsevierpure.com)
  • Patients in arm A will be treated with 3 cycles of R-MP followed by maintenance therapy with procarbazine for 6 months. (biomedcentral.com)
  • Among patients with a complete response, 88% of responders remained in response at 9 months. (ascopost.com)
  • That left a substantial minority of patients in the study still experiencing disease progression following therapy, and 38 percent of the study group died within a median follow-up period of 14.5 months (ranging from 0.4 months to three years). (cancercenter.com)
  • among them, the first cases of autologous stem cell transplants in Vietnam were performed in Hue, which were for patients with metastatic retinoblastoma and recurrent Burkitt Lymphoma. (baothuathienhue.vn)
  • Seven eighty six patients undergoing allogeneic (n=550) or autologous (n=236) BMT were evaluated by physical examination, history, rest and exercise ECG, chest x-ray, two-dimensional echocardiography, and radionuclide ventriculography (RNV) before BMT, and monitored for 5 months thereafter. (slideshare.net)
  • Thirty-eight patients (4.83%) had pathologic findings before transplantation. (slideshare.net)
  • The patients in the small phase I/II trial continued to improve for up to 24 months after the transplantation procedure and then stabilized. (scienceblog.com)
  • The 21 patients in the trial, ages 20 to 53, had relapsing-remitting multiple sclerosis that had not responded to at least six months of treatment with interferon beta. (scienceblog.com)
  • After an average follow-up of three years after transplantation, 17 patients (81 percent) improved by at least one point on a disability scale. (scienceblog.com)
  • Peak CAR T cell expansion was higher in patients with cytokine release syndrome and CAR T-cells remained detectable in the blood in 57% of patients at six months following infusion. (eurekalert.org)
  • Three of nine recipients of FACS-sorted CD34 + HPC demonstrated significant increases in the percentage of γδ + peripheral T cells and CD5 + B cells at 3 to 9 weeks after transplantation, and all patients had transient oligoclonal expansions of T cells expressing specific Vβ TcR. (elsevierpure.com)
  • Transplantation with highly purified CD34 + HPC results in reduced diversity of the peripheral T-cell repertoire during the early post-transplant period compared with patients receiving unmanipulated or MoAb-depleted transplants. (elsevierpure.com)
  • Thirty-six secondary progressive MS patients, among whom 21 were with OSMS and 15 with CMS, underwent APBSCT and were followed up for an average of 48.92Â months (range, 10-91Â months). (cellsurgicalnetwork.com)
  • For the 20 OSMS patients, the overall EDSS score decreased significantly after transplantation (P = 0.016), while visual functions had no significant improvement (P = 0.716). (cellsurgicalnetwork.com)
  • The purpose of this study is to test the benefit of a chemotherapy drug called romidepsin in patients with T Cell Non-Hodgkin Lymphoma (T NHL) who have undergone autologous transplantation. (clinicaltrialsgps.com)
  • Eligible patients were 18 to 65 years of age, had pain for at least 6 months, and had failed conservative therapy. (medscape.com)
  • Patients were excluded if they had received corticosteroid injections in the 3 months preceding study enrollment, were chronic users of nonsteroidal anti-inflammatory drugs, were pregnant, had undergone previous surgery, or had carpal tunnel syndrome , trauma, or some other elbow pathology. (medscape.com)
20221
  • Hou J, Zhang C, Liu C et al (2022) Autologous fine particles fat filling under direct vision in the repair of sunken upper eyelid after double eyelid surgery. (springer.com)
Immunology1
  • We are encouraged by the expansion and persistence of the CAR T-cells, as well as the deep and durable responses with a manageable safety profile we've seen for bb2121 to date," said senior author and principal investigator James N. Kochenderfer, M.D., Experimental Transplantation and Immunology Branch, National Cancer Institute Center for Cancer Research. (eurekalert.org)
Refractory3
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • The manuscript, "Anti-BCMA CAR T Cell Therapy bb2121 in Relapsed/Refractory Multiple Myeloma", published in NEJM include key safety and efficacy results from the dose escalation and first expansion cohort, including a minimum of six months follow up on all subjects. (eurekalert.org)
  • Autologous retinal transplantation may be an option for refractory MTMHs. (bvsalud.org)
Transplant7
  • Risks of infection also vary with the type of transplant, the indication for transplantation, and other host factors. (medscape.com)
  • Blaes AH, Morrison VA: Post-transplant lymphoproliferative disorders following solid-organ transplantation. (karger.com)
  • Yang F, Li Y, Braylan R, Hunger SP, Yang LJ: Pediatric T-cell post-transplant lymphoproliferative disorder after solid organ transplantation. (karger.com)
  • This is the 35th transplant case to be discharged from the hospital and singnifies the anniversary of 35th successful autologous stem cell transplants in children. (baothuathienhue.vn)
  • All but one patient had previously received an autologous stem cell transplant. (eurekalert.org)
  • In both patient groups, the circulating T cells were primarily CD4 - , CD8 + , αβ TcR + , and CD45RO + , CD45RA - during the first 2 months after transplant. (elsevierpure.com)
  • Subsequent increases in the frequency of CD45RA + CD45RO - T cells occurred at 2 to 3 months after transplant, suggesting maturation of CD34 + hematopoietic progenitors to 'naive' T cells. (elsevierpure.com)
Stem cell transplants1
  • CAR T-cell therapy has really begun to displace autologous stem cell transplants as the preferred treatment for diffuse, large B-cell lymphoma [DLBCL] in early first relapse," Dr. Popplewell says. (cancercenter.com)
Kidney transplantation1
Transplants2
  • Transplants from HLA-matched siblings are associated with a lower risk of GVHD and faster recovery of the recipient's immune system following transplantation. (medscape.com)
  • Although liver failure can be treated via hepatocyte transplantation, it also faces multiple problems comprising the shortage of high-quality hepatocytes sources, rejection of allogeneic transplants, difficulty to expand, and losing hepatic characteristics in vitro [ 7 , 8 ]. (springer.com)
Lymphoproliferative disorders1
  • Draoua HY, Tsao L, Mancini DM, Addonizio LJ, Bhagat G, Alobeid B: T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. (karger.com)
Procedure3
  • When the donor is someone other than the recipient, the procedure is described as allogeneic transplantation. (medscape.com)
  • But the costs of total pancreatectomy with islet auto-transplantation have remained fairly high , and the procedure has been neither widespread nor well-studied in the U.S. (medpagetoday.com)
  • In addition we also tested different immunosuppression regimens to demonstrate the feasibility and safety of the NHP EHM construct as well as the transplantation procedure. (ca.gov)
MSCs1
Hematopoietic progenitors1
  • The presence of inflammatory cytokines after high-dose chemotherapy leads to proliferation and activation of MDSCs originating from autologous hematopoietic progenitors at the time of engraftment. (biomedcentral.com)
Recipients1
  • It reportedly occurs primarily in autologous recipients. (nih.gov)
Therapy1
  • This is the first analysis to describe ATLL pathological features, cytogenetics, and response to standard therapy and transplantation in the Caribbean cohort. (oncotarget.com)
Acute2
Myocardial infarction1
Treatment4
  • Despite treatment, ocular OPV PCR test results remained positive until 9 months after onset ( Technical Appendix Table 1), and corneal melting progressed ( Technical Appendix Figure, panel E). Corneal collagen cross-linking and a fourth AMT were performed at 5 months after onset with partial success ( Technical Appendix Figure, panel F). (cdc.gov)
  • An inexorable pattern of progression is characteristic, with a median time to treatment failure of less than 18 months. (medscape.com)
  • The only curative treatment for ALF is liver transplantation, but there are many restrictions on the application of liver transplantation because of financial considerations, a shortage of donor livers, and immunosuppression-related complications [ 3 ]. (springer.com)
  • and six experienced neurological deterioration after transplantation and needed further immunosuppressant treatment. (cellsurgicalnetwork.com)
Significantly1
  • Clinical results showed that the shape of the sunken upper eyelid was significantly improved in 35 cases after correction with this method during the postoperative follow-up from 9 months to 18 months. (springer.com)
Undergone1
  • Various cell types have been tested experimentally for cardiac repair so far, but only those of autologous origin have yet undergone clinical testing due to immune competency. (escardio.org)
Clinical2
  • To report a clinical case study conducted in the Integrated Clinics of the Catholic University of Brasilia in a young melanoderm male patient, 13 years-old, who underwent late tooth transplantation technique, i.e., in two steps: the right upper third molar was transplanted to the socket of the right lower first molar. (bvsalud.org)
  • En route to the patient we can also remove disease-associated genes that might compromise the transplanted cells and eventually the clinical benefit of the graft over time," described Fredrik. (lu.se)
Autogenous1
  • The autogenous transplantation or dental autotransplantation is defined as the replacement of an absent or impaired tooth by another transplanted one, usually the third molar. (bvsalud.org)
AHSCT1
  • Mean follow-up: 99 months in the AHSCT and 91 months in the Cy groups. (unifi.it)
Patient3
  • 13 (39%) were grade ≤ 2 and one patient (3%) had grade 4 neurotoxicity which resolved within one month. (eurekalert.org)
  • The focus was on evaluating the potential of using patient-specific cells (i.e., autologous grafting). (lu.se)
  • My projects investigated whether patient-derived cells are more prone to develop disease phenotypes and what can be done to protect these cells after transplantation," explained Fredrik. (lu.se)
Dose3
  • The second dose of RZV should typically be given 2-6 months after the first. (cdc.gov)
  • However, for persons who are or will be immunodeficient or immunosuppressed and who would benefit from completing the series in a shorter period, the second dose can be administered 1-2 months after the first (2). (cdc.gov)
  • The vaccine series does not need to be restarted if more than 6 months have elapsed since the first dose. (cdc.gov)
Immunosuppression1
Postoperative4
  • And only 1 case had partial depression in the unilateral eyelid and received autologous granular fat transplantation with satisfactory postoperative results. (springer.com)
  • At postoperative month 6, VA was stable at 0.602 ± 0.516 logMAR (P = 0.65). (bvsalud.org)
  • At postoperative month 6, VA improved to 0.555 ± 0.405 logMAR (P (bvsalud.org)
  • At postoperative month 6, VA was stable at 1.000 ± 0.246 logMAR (P = 0.08). (bvsalud.org)
Outcomes1
  • We compared outcomes of consolidation strategies in a minority-rich cohort in the Bronx with limited access to allogeneic transplantation. (elsevierpure.com)
Immune1
  • It will take 6 to 12 months or more for your child's blood counts and immune system to fully recover. (medlineplus.gov)
Donor1
Regimen1